AR090349A1 - Terapia de combinacion para trastornos proliferativos, kit y uso - Google Patents

Terapia de combinacion para trastornos proliferativos, kit y uso

Info

Publication number
AR090349A1
AR090349A1 ARP130100844A ARP130100844A AR090349A1 AR 090349 A1 AR090349 A1 AR 090349A1 AR P130100844 A ARP130100844 A AR P130100844A AR P130100844 A ARP130100844 A AR P130100844A AR 090349 A1 AR090349 A1 AR 090349A1
Authority
AR
Argentina
Prior art keywords
kit
pharmaceutically acceptable
acceptable salt
combination therapy
proliferative disorders
Prior art date
Application number
ARP130100844A
Other languages
English (en)
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR090349A1 publication Critical patent/AR090349A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/402—1-aryl substituted, e.g. piretanide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

Reivindicación 1: Producto farmacéutico que comprende: (i) una primera composición que comprende, a modo de agente activo, vemurafenib, o una sal farmacéuticamente aceptable del mismo, e (ii) una segunda composición que comprende, a modo de agente activo, un inhibidor de MDM2, o una sal farmacéuticamente aceptable del mismo, en forma de preparación combinada para la utilización concomitante o secuencial en el tratamiento del cáncer, siendo la cantidad de dichos agentes activos suficiente para que la combinación de los mismos resulte terapéuticamente efectiva en el tratamiento del cáncer. Reivindicación 9: Producto farmacéutico según cualquiera de las reivindicaciones 1 a 8, en el que dicho inhibidor de MDM2 es el Compuesto (III) de fórmula (1) o una sal farmacéuticamente aceptable de dicho compuesto.
ARP130100844A 2012-03-19 2013-03-15 Terapia de combinacion para trastornos proliferativos, kit y uso AR090349A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261612441P 2012-03-19 2012-03-19

Publications (1)

Publication Number Publication Date
AR090349A1 true AR090349A1 (es) 2014-11-05

Family

ID=47884369

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP130100844A AR090349A1 (es) 2012-03-19 2013-03-15 Terapia de combinacion para trastornos proliferativos, kit y uso

Country Status (16)

Country Link
US (2) US9216170B2 (es)
EP (1) EP2827859B1 (es)
JP (1) JP6141958B2 (es)
KR (1) KR101673731B1 (es)
CN (2) CN108295063A (es)
AR (1) AR090349A1 (es)
AU (1) AU2013203637B2 (es)
BR (1) BR112014018910A8 (es)
CA (1) CA2861056A1 (es)
HK (1) HK1201198A1 (es)
MX (1) MX2014010590A (es)
NZ (1) NZ626985A (es)
RU (1) RU2014141362A (es)
SG (1) SG11201404418QA (es)
WO (1) WO2013139724A1 (es)
ZA (1) ZA201405411B (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101623985B1 (ko) 2007-03-28 2016-05-25 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 스티칭된 폴리펩티드
WO2012021876A2 (en) 2010-08-13 2012-02-16 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
US8709419B2 (en) 2010-08-17 2014-04-29 Hoffmann-La Roche, Inc. Combination therapy
US9295669B2 (en) 2010-12-14 2016-03-29 Hoffman La-Roche Inc. Combination therapy for proliferative disorders
TWI643868B (zh) 2011-10-18 2018-12-11 艾利倫治療公司 擬肽巨環化合物
US20140200255A1 (en) 2012-03-19 2014-07-17 Brian Higgins Method for administration
US9216170B2 (en) 2012-03-19 2015-12-22 Hoffmann-La Roche Inc. Combination therapy for proliferative disorders
US20130245089A1 (en) 2012-03-19 2013-09-19 Hoffmann-La Roche Inc. Method for administration
SG10201913359TA (en) 2012-08-17 2020-02-27 Hoffmann La Roche Combination therapies for melanoma comprising administering cobimetinib and vemurafinib
EP2914256B1 (en) 2012-11-01 2019-07-31 Aileron Therapeutics, Inc. Disubstituted amino acids and methods of preparation and use thereof
BR112016010564A2 (pt) 2013-11-11 2017-10-10 Amgen Inc terapia de combinação incluindo um inibidor de mdm2 e um ou mais agentes farmaceuticamente ativos para tratamento de cânceres
WO2015084804A1 (en) 2013-12-03 2015-06-11 Novartis Ag Combination of mdm2 inhibitor and braf inhibitor and their use
PE20160591A1 (es) * 2013-12-05 2016-06-11 Hoffmann La Roche Nuevo tratamiento de combinacion para la leucemia mieloide aguda (lma)
CN106458886A (zh) * 2014-04-15 2017-02-22 豪夫迈·罗氏有限公司 药物活性化合物的固体形式
TW201613576A (en) * 2014-06-26 2016-04-16 Novartis Ag Intermittent dosing of MDM2 inhibitor
CN106999541A (zh) 2014-09-24 2017-08-01 艾瑞朗医疗公司 拟肽大环化合物及其用途
CA2961029A1 (en) 2014-09-24 2016-03-31 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and formulations thereof
CA2972076A1 (en) * 2014-12-23 2016-06-30 Millennium Pharmaceuticals, Inc. Combination of raf inhibitors and aurora kinase inhibitors
TWI711452B (zh) 2015-02-20 2020-12-01 日商第一三共股份有限公司 癌症的倂用治療法
MX2017011834A (es) 2015-03-20 2018-04-11 Aileron Therapeutics Inc Macrociclos peptidomimeticos y usos de los mismos.
CN108368161A (zh) 2015-09-10 2018-08-03 艾瑞朗医疗公司 作为mcl-1调节剂的拟肽大环化合物
WO2017066193A1 (en) 2015-10-15 2017-04-20 Princeton Drug Discovery, Llc Novel inhibitors of protein kinases
EP3391643A4 (en) 2015-12-14 2019-07-31 Red.Com, Llc MODULAR DIGITAL CAMERA AND MOBILE PHONE
JP7300394B2 (ja) 2017-01-17 2023-06-29 ヘパリジェニックス ゲーエムベーハー 肝再生の促進又は肝細胞死の低減もしくは予防のためのプロテインキナーゼ阻害
US11091522B2 (en) 2018-07-23 2021-08-17 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
CN110585433A (zh) * 2019-09-27 2019-12-20 青岛大学 Braf-v600e的抑制剂的应用及用于治疗甲状腺癌的药物

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5138938B2 (ja) 2003-12-19 2013-02-06 プレキシコン インコーポレーテッド Ｒｅｔ調節剤の開発のための化合物および方法
RS52010B (en) 2005-06-22 2012-04-30 Plexxikon Inc. DERIVATI PIROLO [2, 3-B] PIRIDINA KAO INHIBITORI PROTEIN KINAZE
BRPI0619236A2 (pt) 2005-12-01 2011-09-20 Hoffmann La Roche derivados de 2,4,5-trifenil imidazolina, composição farmacêutica que os compreende, uso e processo para a sìntese dos mesmos
US8354444B2 (en) 2008-09-18 2013-01-15 Hoffmann-La Roche Inc. Substituted pyrrolidine-2-carboxamides
NZ594398A (en) 2009-04-03 2014-03-28 Plexxikon Inc Propane-1-sulfonic acid (3-[5-(4-chloro-phenyl)-1h-pyrrol [2, 3-b] pyridine-3-carbonyl]-2,4-difluoro-phenyl} -amide compositions and uses thereof
US8329724B2 (en) 2009-08-03 2012-12-11 Hoffmann-La Roche Inc. Process for the manufacture of pharmaceutically active compounds
SG10201402917XA (en) 2009-08-24 2014-08-28 Genentech Inc Determining sensitivity of cells to b-raf inhibitor treatment by detecting kras mutation and rtk expression levels
US8779150B2 (en) 2010-07-21 2014-07-15 Hoffmann-La Roche Inc. Processes for the manufacture of propane-1-sulfonic acid {3-[5-(4-chloro-phenyl)-1 H-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluoro-phenyl}-amide
US20120045433A1 (en) 2010-08-17 2012-02-23 Kapil Dhingra Combination therapy
US8709419B2 (en) 2010-08-17 2014-04-29 Hoffmann-La Roche, Inc. Combination therapy
US9295669B2 (en) 2010-12-14 2016-03-29 Hoffman La-Roche Inc. Combination therapy for proliferative disorders
AR085279A1 (es) 2011-02-21 2013-09-18 Plexxikon Inc Formas solidas de {3-[5-(4-cloro-fenil)-1h-pirrolo[2,3-b]piridina-3-carbonil]-2,4-difluor-fenil}-amida del acido propano-1-sulfonico
KR20140025434A (ko) 2011-04-01 2014-03-04 제넨테크, 인크. Akt 억제제 화합물 및 화학요법제의 조합물, 및 사용 방법
BR112014009953A2 (pt) 2011-10-28 2017-12-05 Genentech Inc método de inibição do crescimento de tumores, de tratamento de melanoma, artigo industrializado e uso
US20130172375A1 (en) 2011-12-13 2013-07-04 Hoffmann-La Roche Inc. Pharmaceutical composition
US9216170B2 (en) 2012-03-19 2015-12-22 Hoffmann-La Roche Inc. Combination therapy for proliferative disorders

Also Published As

Publication number Publication date
CA2861056A1 (en) 2013-09-26
HK1201198A1 (en) 2015-08-28
MX2014010590A (es) 2014-09-18
CN104114168A (zh) 2014-10-22
US9216170B2 (en) 2015-12-22
CN108295063A (zh) 2018-07-20
KR20140130179A (ko) 2014-11-07
AU2013203637B2 (en) 2016-07-07
WO2013139724A1 (en) 2013-09-26
BR112014018910A8 (pt) 2017-07-11
BR112014018910A2 (es) 2017-06-20
KR101673731B1 (ko) 2016-11-07
RU2014141362A (ru) 2016-05-10
EP2827859A1 (en) 2015-01-28
US20130245039A1 (en) 2013-09-19
US20160051525A1 (en) 2016-02-25
EP2827859B1 (en) 2018-10-17
JP6141958B2 (ja) 2017-06-07
SG11201404418QA (en) 2014-10-30
AU2013203637A1 (en) 2013-10-03
US9486445B2 (en) 2016-11-08
NZ626985A (en) 2016-07-29
ZA201405411B (en) 2019-09-25
JP2015510908A (ja) 2015-04-13

Similar Documents

Publication Publication Date Title
AR090349A1 (es) Terapia de combinacion para trastornos proliferativos, kit y uso
CR20150628A (es) Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades
CL2018000318A1 (es) Compuestos derivados de piridinona, inhibidores de bromodominio; composición farmacéutica que los comprende; y su uso en el tratamiento de enfermedades del cáncer. (solicitud divisional 201600925)
AR072442A1 (es) Metodo para la terapia del cancer, uso, kit
BR112015029491A2 (pt) derivados de imidazopirrolidinona e seu uso no tratamento de doença
BR112016002287A2 (pt) compostos terapeuticamente ativos e seus métodos de uso
AR084691A1 (es) Formulacion de uso topico para un inhibidor de jak y metodo para tratar trastorno de la piel
AR107871A1 (es) Combinaciones de inhibidores de lsd1 para su uso en el tratamiento de tumores sólidos
BR112016000561B8 (pt) Compostos terapeuticamente ativos, uso dos mesmos, composição farmacêutica e uso da mesma
RU2013121788A (ru) Ингибиторы репликации вич
MX345928B (es) Composiciones terapeuticamente activas y metodos de uso de las mismas.
BR112015029401A8 (pt) derivados de pirazolo-pirrolidin-4-ona, seus usos, e composição e combinação farmacêuticas
AR085662A1 (es) Metodos y composiciones para tratar la hiperuricemia y trastornos metabolicos asociados con la hiperuricemia
AR096892A1 (es) Una combinación farmacéutica para el tratamiento del melanoma
RU2018135973A (ru) Фармацевтическая комбинация, содержащая метроформин и дигидрокверценин, и ее применение для лечения рака
CO6280574A2 (es) Metodos para utilizar antagonistas de vasopresina con agentes de quimioterapia con antraciclina para reducir la cardiotoxicidad y/o para mejorar la supervivencia
AR097619A1 (es) Uso de inhibidores de acetil-coa carboxilasa para tratar acné vulgaris
ECSP19026973A (es) Derivados de naftiridinona y su uso en el tratamiento de la arritmia
CL2010000524A1 (es) Uso de una composición tópica que comprende 3,75% de imiquimod y un portador farmacéuticamente aceptable para preparar un medicamento útil para tratar verrugas genitales o perianales.
AR085132A1 (es) Composiciones farmaceuticas para el tratamiento de glioma maligno
UY31826A (es) Compuesto peptídico y su uso
EA201591653A1 (ru) Композиции для лечения глазных расстройств с применением дипиридамола
AR108792A1 (es) Composiciones que comprenden timolol
UY33806A (es) ?compuestos novedosos de imidazoquinolina, composiciones que los contienen y su uso en el tratamiento de enfermedades mediadas por tlr7?
CL2022003039A1 (es) Inhibidores de il4i1 y métodos de uso.

Legal Events

Date Code Title Description
FB Suspension of granting procedure